Upon joining the study, you will be randomly assigned to one of several treatment groups. This means that a computer program will decide which treatment you receive, similar to flipping a coin.

You may receive LAD191 (the medication being tested), adalimumab (an approved medication for comparison), or placebo (an inactive substance that looks like the medication but contains no active ingredients).

Neither you nor your doctor will know which treatment you are receiving during the study. This is called a double-blind design and helps ensure accurate results.

The study medication will be administered as an injection under the skin, which is called subcutaneous injection.

The injection will be given in the fatty tissue just beneath the skin surface.

The study products include LAD191 solution for injection, adalimumab for injection, or placebo.

Throughout the entire study, you will be required to regularly use over-the-counter topical antiseptics on your hidradenitis suppurativa lesions.

These are cleaning products that help reduce bacteria on the skin and can be purchased without a prescription.

You should apply these antiseptics preferably daily, but at least 3 days per week for the duration of the study.

You will attend scheduled visits at the study site throughout the treatment period.

During these visits, the study team will examine your hidradenitis suppurativa lesions, counting abscesses (pockets of pus under the skin) and inflammatory nodules (painful lumps under the skin).

Your vital signs, such as blood pressure, heart rate, and temperature, will be measured.

Electrocardiograms (ECGs), which are tests that measure the electrical activity of your heart, will be performed.

Blood and other laboratory samples will be collected to monitor your health and check for any side effects.

The study team will regularly assess whether your condition is improving using a measurement called HiSCR 50.

This measurement evaluates whether there has been at least a 50% reduction in the number of abscesses and inflammatory nodules, with no increase in the number of abscesses or draining tunnels under the skin.

This assessment helps determine if the treatment is working for your hidradenitis suppurativa.

Throughout the study, you will be monitored for any adverse events, which are any unwanted or harmful effects that occur during treatment.

The study team will check for reactions at the injection site, such as redness, swelling, or pain.

Any side effects you experience, whether mild or serious, will be recorded and evaluated.

If you experience any serious adverse events or side effects that are difficult to tolerate, your treatment may be stopped.

The study uses an adaptive design, which means that decisions about treatment doses and duration may be adjusted based on results observed during the study.

You will continue receiving your assigned treatment according to the schedule determined for your treatment group.

The exact duration of treatment will depend on the specific dosing regimen you are assigned to.

If you are a woman who can become pregnant or a male participant, you must follow specific requirements to prevent pregnancy during the study.

These measures are necessary to avoid potential exposure of an unborn child to the study medication.

You will need to agree to use appropriate contraceptive methods as specified in the study requirements.

The study is expected to continue until approximately July 2027.

You will be informed about the specific duration of your participation based on your treatment group.

Final assessments will be conducted to evaluate the overall effect of the treatment on your hidradenitis suppurativa and your general health.